Skip to search formSkip to main contentSkip to account menu

ramosetron

Known as: 5-((1-methyl-3-indolyl)carbonyl)-4,5,6,7-tetrahydro-1H-benzimidazol 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

AntiemeticsBenzimidazolesSerotonin Antagonists

Narrower (2)

NaseaYM 060
ramosetron hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Palonosetron has superior prophylactic antiemetic efficacy compared with ondansetron or ramosetron in high-risk patients undergoing laparoscopic surgery: a prospective, randomized, double-blinded…
Background Postoperative nausea and vomiting (PONV) continues to be a major problem, because PONV is associated with delayed… 
2012
2012
Dual role of serotonin in the pathogenesis of indomethacin-induced small intestinal ulceration: pro-ulcerogenic action via 5-HT3 receptors and anti-ulcerogenic action via 5-HT4 receptors.
2012
2012
Tauro-β-muricholic acid restricts bile acid-induced hepatocellular apoptosis by preserving the mitochondrial membrane potential.
2011
2011
Comparison of ramosetron's and ondansetron's preventive anti-emetic effects in highly susceptible patients undergoing abdominal hysterectomy
Background This study compared the preventive effects of ramosetron and ondansetron on postoperative nausea and vomiting (PONV… 
Highly Cited
2009
Highly Cited
2009
Comparison of ramosetron with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery.
BACKGROUND Ramosetron is a new selective 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonist that reportedly has more potent… 
2007
2007
Ramosetron versus Ondansetron in the Prevention of Chemotherapy-Induced Gastrointestinal Side Effects: A Prospective Randomized Controlled Study
Background: This study observed and compared the preventive effects of ramosetron and ondansetron on gastrointestinal side… 
2007
2007
Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.
We examined the pharmacological profile of ramosetron, a 5-HT(3)-receptor antagonist for irritable bowel syndrome with diarrhea… 
Review
2002
Review
2002
Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting.
Ramosetron is a selective serotonin 5-HT3 receptor antagonist with an affinity higher than that of the previously available drugs… 
2002
2002
Ramosetron for the Prevention of Cisplatin-Induced Acute Emesis: A Prospective Randomized Comparison with Granisetron
Control of nausea and vomiting is very important in determining patient compliance with cisplatin chemotherapy. A multicentre… 
Highly Cited
1999
Highly Cited
1999
Comparison of ramosetron and granisetron for preventing postoperative nausea and vomiting after gynecologic surgery.
UNLABELLED In a prospective, randomized, double-blinded study, we evaluated the efficacy of granisetron and ramosetron for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)